Kraig Biocraft Laboratories submits Provisional Patent Applications on multiple Spider Silk Technologies

ANN ARBOR, Mich., – May 22, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has submitted five new provisional patent applications, for technologies related to its recombinant spider silk technologies.  These applications cover a broad range of technologies in the creation, screening, and production of new recombinant proteins.  These new applications expand beyond the Company’s publicly disclosed silkworm and silk technologies, to include advanced construction systems, methods, and non-native proteins. 

In November, of 2018, the Company retained Workman Nydegger as its Intellectual Property counsel and expects to utilize their expertise in prosecuting these, and all future, patent applications.

“Our R&D team is constantly looking for opportunities to strengthen our competitive potions, products, and processes. The recently submitted provisional patent applications cover key technologies and processes, invented by Dr. Kane and our team, as well as new applications that build upon our technologies,” said Kraig’s COO Jon Rice.  “These new technologies have the potential to significantly reduce future R&D costs and break open new markets for recombinant protein products, reaching far beyond silks and apparel.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories takes possession of factory in Vietnam

ANN ARBOR, Mich., – May 20, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that its subsidiary Prodigy Textiles has taken possession of its factory in Vietnam.  The Company is now retrofitting the nearly 50,000 square foot facility to produce its game changing recombinant spider silk materials.   Remodeling efforts are expected to be minimal and completed quickly.  This facility was selected based on its optimal layout and existing infrastructure. 

“Our people on the ground, in Vietnam, are wasting no time getting this facility into operation.  We have outlined a very aggressive timeline for bringing the factory online and we are monitoring progress daily,” said Kraig’s COO Jon Rice.  “We are very pleased to see how quickly things are moving and look forward to completing the transition.  We expect to make delivery of the first production batch, of our recombinant spider silk thread, from this factory to one of our strategic market channel partners in the third or fourth quarter.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories to be featured in upcoming documentary series on combating terrorism

Kraig Labs opens R&D headquarters to media for the first time

ANN ARBOR, Mich., – May 13, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that its recombinant spider silk technology will be featured in a documentary focused on combating terrorism.  The Company opened the doors of its R&D headquarters, for the first time to the media, to host a French documentary film crew and provided them with access to the process of creating its incredible spider silk technologies.

Tougher and more flexible than competing materials, spider silk offers the promise of increased protection, comfort, and mobility in protective textile applications. In addition to this documentary, the Company has been covered by numerous media outlets, including the following T.EVO, Textile Evolution, article; https://www.tevonews.com/fibres-yarns-news/2026-polartec-figureheads-discuss-kraig-labs-silkworm-solution.

“Our team is incredibly proud of the work we do here and the impact that our Company is already making in these important markets,” said COO Jon Rice.  “It was a pleasure to be able to share the results of our efforts and to showcase this amazing technology along with its potential to disrupt the protective textile and related markets.”

The series is planned to air in the fall of 2019.  Although the footage was shot at Kraig Labs’ R&D headquarters in Michigan, the Company continues to focus its efforts on scaling up its production operations, through its subsidiary, Prodigy Textiles Ltd., in Asia.  By utilizing the existing global silk infrastructure and Kraig Labs’ engineered silkworm technology, the Company set to meet cost and volume metrics, previously thought to be impossible, in the commercialization of spider silk for these lifesaving applications in protective textiles.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories expands production footprint in Vietnam

Kraig Labs signs factory lease to expand production capacity

ANN ARBOR, Mich., – May 7, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that, through its subsidiary Prodigy Textiles, the Company has signed a new 5 year lease on a factory, expanding its production footprint in Vietnam.  The roughly 50,000 ft2 facility in Quang Nam province is expected to play a major role in supporting the Company’s increasing production capacity of its proprietary recombinant spider silk technologies.

“Our team in Vietnam, led by Mr. Kenneth Le, has done an excellent job of scouting, selecting, and negotiating the terms of this deal.  With its close proximity to the necessary mulberry fields, and easy access to shipping ports, this facility will serve as a springboard for Kraig Labs introduction of spider silk into the global textile markets,” said COO Jon Rice.

The Company expects to begin transferring its technology into the larger factory from the temporary facility that Prodigy Textiles has been utilizing since December of 2018.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories to expand Corporate Board of Directors

Additional independent directors to help advance Kraig Labs’ business model

ANN ARBOR, Mich., – April 29, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that it has initiated the process of identifying qualified corporate leaders, to assist in the Company’s growth, as it plans to add two new independent corporate board directors.

“With the successful delivery of our proprietary spider silk technology to Prodigy Textiles, our Vietnamese subsidiary, we are now moving into the production phase of our business plan. We believe that this is the right moment to bring on additional expertise to support the Company’s efforts to bring spider silk to the performance textile markets.   The addition of these new board members will assist our growth through this exciting transition to commercialization and help keep our focus on continuing to create shareholder value,” stated COO, Jon Rice. 

Expanding the Board of Directors is an important advancement in Kraig Labs’ business model and is an important milestone for the Company as it contemplates uplisting to a larger exchange.

“We plan to conduct a careful search, to identify independent board members who can contribute expertise and crucial market experience, as we look to rapidly grow our capacity and expand our strategic market channel partner networks,” said CEO and Founder, Kim Thompson. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies.

The Company achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Polartec and Kraig Biocraft Laboratories to Bring First Spider Silk Fabrics to the Performance Apparel Market

(Andover, Mass.) – April 17, 2019 – Polartec, the premium provider of innovative and sustainable textile solutions, and Kraig Biocraft Laboratories (Kraig) (OTC:KBLB), the biotechnology company focused on the development and commercialization of spider silk, announce plans to bring to market the first fabrics made from spider silk. Initially developed for specialized military applications, these first-of-their-kind materials made from recombinant spider silk will eventually service the global market for high performance textiles and apparel.

Among the strongest fibers produced in nature, scalable and cost-effective production of spider silk represents a ‘holy grail’ of material science. Kraig possesses the exclusive right to use patented spider silk gene sequences in silkworms, which is the first way to mass produce these fibers cost effectively and responsibly. (Spiders cannot be raised in colonies and competitors rely on genetically engineered E.coli bacteria to make silk, which produces high levels of carbon dioxide in addition to being cost prohibitive.)

“Teaming with an industry leader such as Polartec is a real endorsement of our proprietary approach to unlocking the potential of commercially-produced spider silk,” says Kim Thompson, Kraig Laboratories founder and CEO. “Kraig believes that spider silk, with its superior mechanical characteristics, has the potential to surpass the current generation of high performance fibers.”

These fully renewable, biodegradable and biocompatible ‘super fibers’ are thin, lightweight, flexible, resilient, extraordinarily strong, and display strength-to-weight ratios more comparable to aramid fibers than other current performance fibers. In apparel applications, the possibilities of recombinant spider silks are particularly exciting, realizing unprecedented combinations of physical properties such as luxurious feel and breathable comfort with top durability.

In joint development since 2016, Polartec and Kraig are applying the performance characteristics of spider silk into yarns for military-grade textiles.

“This project combines two of our most important innovation missions: providing best-in-class textiles to our Nation’s military personnel, and our investment in a fully biodegradable product line,” says Gary Smith, Polartec CEO. “Our partnership with Kraig has the potential to be as revolutionary as when we created the first performance fabrics made from post-consumer recycled plastics in 1993.”

Polartec recently announced its Polartec Eco-Engineering™ commitment to using 100% biodegradable and recycled materials across its entire product line through another partnership with Unifi and CiCLO. For example, this new standard for sustainable textiles will include the creation of the world’s first fully recycled and biodegradable fleece, other knits, insulation fills and breathable waterproof fabrics.

About Polartec

Polartec is the premium provider of innovative and sustainable textile solutions. Since inventing modern technical fleece in 1981, the engineers at Polartec continue to advance the science of fabric, creating fabric technologies that solve problems and improve the way products are designed and used. Polartec products range from lightweight wicking and cooling fabrics, to insulation and weather protection textiles, and are utilized by leading consumer brands, the U.S. Military and other global militaries, flame resistance, workwear, and contract upholstery markets. For more information, please visit Polartec.com and follow Polartec on Instagram, Facebook and Twitter.

About Kraig Biocraft Laboratories

Kraig Labs (OTC: KBLB) is the leading developer of genetically engineered spider silk based fiber technologies. Kraig’s recombinant spider silk fibers are lighter, stronger, and more flexible than traditional materials, offering unmatched material performance with sustainable and ecological manufacturing practices. For more information, please visit Kraiglabs.com and follow Kraig Labs on Facebook and Twitter

 

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the two Companies’ futures and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Companies’ business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

This entry was posted on by .

University of Notre Dame increases equity position in Kraig Biocraft Laboratories

ANN ARBOR, Mich., – March 13, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has signed an agreement with the University of Notre Dame, which increases the University’s equity position in Kraig Labs.  Under the agreement, the University has converted a portion of the moneys owed to it, by the Company, to common stock.  The remaining balance of the moneys, owed to the University, has been converted into a note that is payable over the course of 2 years.

Kraig Labs has worked in collaboration with the University of Notre Dame, for 10 years, developing the Company’s recombinant spider silk technologies.

“The Notre Dame IDEA Center is excited by the commercial prospects in front of Kraig Biocraft and is pleased to be able to conclude this most recent agreement, which gives Kraig some additional runway to continue its development of commercial spider silk products,” said Notre Dame’s Richard Cox, Director, Licensing & Business Development

“We have been working with Notre Dame on this deal for quite some time.  Today, we are pleased to report that, having now finalized this agreement, they have nearly tripled their equity position in the Company,” said COO Jon Rice.  “The deal has strengthened the Company’s balance sheet and, in conjunction with the equity financing announced Monday, improves our financial position, as we move towards larger scale production.” 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Closes Financing Deal

Kraig Labs secures funding to expand production of its recombinant spider silk

ANN ARBOR, Mich., – March 11, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has closed a $1 million round of private financing, pursuant to Regulation S of the Securities Act of 1933, as amended (the “Securities Act”), to fund expansion of its recombinant spider silk production in Vietnam, support its advanced research operations, improve its balance sheet, and to support other corporate initiatives.

A core focus for this funding will be to support the growth of operations at the Company’s new production facility in Quang Nam Province, Vietnam.  With this funding in place, the Company plans to ramp up its silk production at this larger factory.

“Securing this bridge financing was a key piece to funding the Company’s commercial expansion strategy and puts us in a strong position as we shift operational focus to production,” said COO Jon Rice.  “This capital is necessary to support commercial expansion, which is essential in establishing market channel collaborations for consumer products.”

Under the terms of the stock purchase agreement, the Company issued shares of its class A common stock at a price of $0.06758 per share and warrants to purchase additional shares of its class A common stock at exercise prices of $0.06 and $0.08. 

Additional details about the financing will be filed on a Current Report on Form 8-K with the Securities and Exchange Commission and available under “Investor Relations – SEC Filings” at www.kraiglabs.com/sec-filings/.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the securities mentioned in this press release in any state in which such offer, solicitation or sale would be unlawful.  The securities have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories’ Spider Silk Technology Successfully Delivered to Vietnam

Monumental Breakthrough for Large Scale Commercialization of Spider Silk

ANN ARBOR, Mich., – January 7, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has successfully delivered the first two shipments of its highly specialized silkworms, which produce a silk with the physical characteristics of spider silk, to Vietnam.

Today’s announcement is the culmination of more than 5 years of work, and challenging negotiation, with the government of Vietnam. The silkworms from these first two shipments have already hatched and are now enjoying a fresh mulberry diet, so, for the first time in history, the global demand for spider silk materials has a viable, cost effective, and scalable solution.

“The dream of commercializing our powerful technology is now materializing. This marks a dramatic leap forward in Kraig Labs’ business plan for commercial production and mass marketing of cost effective recombinant spider silk, and becomes the foundation for an entirely new industry,” said, COO, Jon Rice. “To our long-term shareholders, who have taken this journey with us, as well as our team in the US and Vietnam, who have worked tirelessly to make this dream a reality, I cannot thank you enough. As we start the New Year, full of new opportunity, we truly have something incredible to celebrate.”

The Company has been working with leading sericulture experts, biotechnology institutions, and governmental agencies, in Vietnam, to further boost the silk industry with our revolutionary technology. Kraig Labs is currently finalizing renovation plans for a ~46,000 square foot production factory in Quang Nam Province, Vietnam.

“Our plan has always been to bring our technology to the silk producing regions of the world for rapid scale-up,” said, CEO and Founder, Kim Thompson. “Today we see the fruits of that effort. With its massive silk infrastructure and production capacity, Vietnam is an ideal location to launch our technology scale-up. Congratulations to our team and shareholders, as we prepare for the realization of large scale production.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories completes Final Facilities Review for First Batch of Recombinant Spider Silk Production in Vietnam

ANN ARBOR, Mich., – January 3, 2018 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that key members of its management and production team have laid the groundwork for the Company’s Vietnamese spider silk production initiative. 

Working through an MOU, announced in November, the Company is collaborating with the Institute of Biotechnology – Vietnam Academy of Science and Technology (“IBT”) and Vietnam Sericulture Research Centre (“VSRC”) to rear and test the first ever recombinant spider silk silkworms in Vietnam.  The Kraig Labs team, in partnership with its subsidiary, Prodigy Textiles Co Ltd., held a series of meetings with senior members of the IBT and the VSRC to outline the project requirements and to review the facilities selected to raise the first batch of transgenic silkworms. 

The Kraig Labs team visited the IBT headquarters and brand new satellite location, where the team members reviewed IBT’s laboratory capabilities and discussed possible future collaborative research efforts. 

The team also spent time at the VSRC headquarters reviewing their rearing processes, discussing the details of the Company’s transgenic silkworms, and outlining requirements for hatching the Company’s silkworms.

The Company’s technology is designed to work hand-in-glove with existing silk production infrastructure, of which and is why the Company focused its efforts in Vietnam because of the existing infrastructure and history of silk manufacturing, which would theoretically allow for very rapid expansion of production.  With everything in place, Kraig Labs’ team believes that the Company is the verge of a major breakthrough in the commercialization of spider silk. 

“The silk experts of the VSRC, working in partnership with members of our Prodigy Textiles team, will give our expansion in Vietnam a strong foundation,” said COO Jon Rice.  “That expertise, combined with IBT’s facilities and capabilities, should pave the way to success, for this first of its kind effort, and translate into a smooth production scale up.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .